TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: A Study Comparing Obinutuzumab (RO5072759; GA101) 1000 Milligram (mg) Versus 2000 mg in Participants With Previously Untreated Chronic Lymphocytic Leukemia (CLL) (GAGE)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Confirmed diagnosis of CD20-positive B-cell CLL (per International Workshop on Chronic Lymphocytic Leukemia \[IWCLL\] guidelines)~* Rai Stage III/IV or Binet Stage C disease, or Rai Stage I/II or Binet Stage B disease that requires treatment according to IWCLL guidelines~* No previous treatment for CLL chemotherapy, radiotherapy or immunotherapy; no previous rituximab treatment for autoimmune hemolytic anemia (AIHA) or idiopathic thrombocytopenic purpura (ITP); prior use of steroids for AIHA or ITP is allowed~* Eastern Cooperative Oncology Group performance status of 0, 1 or 2~Exclusion Criteria:~* Confirmed diagnosis of Transformation of CLL to aggressive B-cell malignancy~* History of severe allergic or anaphylactic reactions to monoclonal antibody therapy~* Evidence of severe, uncontrolled concomitant disease~* Known active infection or any major episode of infection requiring treatment with IV antibiotics or hospitalization within 4 weeks before the start of Cycle 1~* Seropositive for human immunodeficiency virus (HIV)~* Positive for chronic hepatitis B infection (defined as positive hepatitis B surface antigen \[HBsAg\] serology)~* Positive for hepatitis C (hepatitis C virus \[HCV\] antibody serology testing)~* Pregnant or lactating women~* Concurrent (or within 7 days prior to first dose of study treatment) systemic corticosteroid use, except for low-dose corticosteroid therapy used to treat chronic medical conditions

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Obinutuzumab 1000 mg (Type: EXPERIMENTAL): Participants received a 1000 mg intravenous (IV) infusion, on days 1 (split dose 100 mg on Day 1 and 900 mg on Day 2), 8 and 15 of cycle 1 and day 1 of cycles 2 - 8, 21 day cycles. All participants received corticosteroids IV prior to the initial dose.
- Obinutuzumab 2000 mg (Type: EXPERIMENTAL): Participants received a 2000 mg IV infusion, on days 1 (split dose 100 mg Day 1, 900 mg Day 2 and 1000 mg Day 3), 8 and 15 of cycle 1 and day 1 of cycles 2 -8, 21 day cycles. All participants received corticosteroids IV prior to the initial dose.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effects of Dipeptidyl Peptidase-4 (DPP-4) Inhibition on Hormonal Responses to Macronutrient Ingestion

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy men~* Age 20-30 years~* BMI 20-30 kg/m2~Exclusion Criteria:~* Any disease~* Any medication

- Gender: MALE
- Minimum Age: 20 Years
- Maximum Age: 30 Years
- Healthy Volunteers: t

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): A placebo tablet is given before ingestion of macronutrients
- Sitagliptin (Type: ACTIVE_COMPARATOR): Sitagliptin is given before ingestion of macronutrients

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Multiple-dose,Double-blind,Placebo-controlled Study of Sodium Oxybate in Patients With Essential Tremor

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of moderate or severe classic essential tremor (bilateral, largely symmetric postural or kinetic tremor involving hands and forearms.~* Willingness to abstain from ethanol and caffeine intake for at least 48 hours prior to Days 1 and 4 and on inpatient days~Exclusion Criteria:~* Subjects with a clinically significant unstable medical abnormality, chronic disease or history or presence of significant hepatic, renal, endocrine, cardiovascular, gastrointestinal, pulmonary, psychiatric, or metabolic disease or any other abnormality~* Subjects who are on sodium-restricted diets~* Subjects with a known history of sleep apnea

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None
- 2 (Type: EXPERIMENTAL): None
- 3 (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of TMC435 in Combination With Pegylated Interferon Alp\Fa-2a and Ribavirin in Patients Infected With Genotype 1 Hepatitis C Virus Who Never Received Treatment

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with documented chronic genotype-1 hepatitis C infection and with plasma HCV RNA of \> 100,000 IU/mL at screening~* Patients that have not been treated before for HCV~* Patients that are of childbearing potential or have a partner of childbearing potential should agree to use 2 effective methods of contraception~Exclusion Criteria:~* Patients with cirrhosis or evidence of hepatic decompensation~* Co-infection with the human immunodeficiency virus (HIV)~* Any contraindication to Pegasys or Copegus therapy~* History of, or any current medical condition which could impact the safety of the patient in the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- TMC435 75 mg 12 Wks + PR 24/48 (Type: EXPERIMENTAL): Participants will receive TMC435 75 mg once daily with PegIFNα-2a (P) once weekly and ribavirin (R) twice daily for 12 weeks followed by Placebo once daily and PR for 12 weeks. Treatment with PR was stopped at Week 24 for participants who met response-guided treatment (RGT) criteria. All other participants continued PR until Week 48.
- TMC435 75 mg 24 Wks + PR 24/48 (Type: EXPERIMENTAL): Participants will receive TMC435 75 mg once daily with PegIFNα-2a (P) once weekly and ribavirin (R) twice daily for 24 weeks. Treatment with PR was stopped at Week 24 for participants who met response-guided treatment (RGT) criteria. All other participants continued PR until Week 48.
- TMC435 150 mg 12 Wks + PR 24/48 (Type: EXPERIMENTAL): Participants will receive TMC435 150 mg once daily with PegIFNα-2a (P) once weekly and ribavirin (R) twice daily for 12 weeks followed Placebo and PR for 12 weeks. Treatment with PR was stopped at Week 24 for participants who met response-guided treatment (RGT) criteria. All other participants continued PR until Week 48.
- TMC435 150 mg 24 Wks + PR 24/48 (Type: EXPERIMENTAL): Participants will receive TMC435 150 mg once daily with PegIFNα-2a (P) and ribavirin (R) for 24 weeks. Treatment with PR was stopped at Week 24 for participants who met response-guided treatment (RGT) criteria. All other participants continued PR until Week 48.
- Placebo 24 Wks + PR48 (Type: PLACEBO_COMPARATOR): Participants will receive Placebo once daily with PegIFNα-2a (P) and ribavirin (R) for 24 weeks followed by PR until Week 48.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Avastin (Bevacizumab) Plus Crossover Fluoropyrimidine-Based Chemotherapy in Patients With Metastatic Colorectal Cancer.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adult patients, \>=18 years of age~* Metastatic colorectal cancer and disease progression~* Previously treated with first-line chemotherapy plus Avastin~* Eastern Cooperative Oncology Group (ECOG) performance status \<=2.~Exclusion Criteria:~* Diagnosis of progression of disease more than 3 months after last Avastin administration~* First-line patients with progression-free survival in first-line of \<3 months~* Patients receiving less than 3 consecutive months of Avastin in first-line therapy~* Past or current history (within the last 2 years prior to treatment start) of other malignancies, except for curatively treated basal and squamous cell cancer of the skin or in situ cancer of the cervix~* Clinically significant cardiovascular disease within 6 months prior to start of study treatment~* Known central nervous system (CNS) disease, except for treated CNS metastases as defined by protocol

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Chemotherapy (Type: ACTIVE_COMPARATOR): Chemotherapy alone until disease progression, unacceptable toxicity, or patient refusal
- Chemotherapy + Bevacizumab (Type: EXPERIMENTAL): Chemotherapy and Bevacizumab until disease progression, unacceptable toxicity, or patient refusal

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of Alvimopan for the Management of Opioid-induced Postoperative Bowel Dysfunction/Postoperative Ileus

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Subject is scheduled for a partial small/large bowel resection with primary anastomosis; all procedures must be performed completely by open laparotomy.~* Subject is scheduled to receive primary postoperative pain management with intravenous (i.v.) patient-controlled analgesia (PCA) opioids.~Exclusion Criteria:~* Subject is scheduled for a total colectomy, colostomy, ileostomy, any laparoscopic or laparoscopically-assisted procedure, or subject has a history of gastrectomy, total colectomy, short bowel syndrome, or multiple previous abdominal surgeries performed by open laparotomy.~* Subject has complete bowel obstruction.~* Subject is currently taking opioid analgesics or has taken more than three doses of opioids (oral or parenteral) within the previous 7 days prior to the day of surgery.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Intermittent Pneumatic Compression Device for Vein Dilation in Kidney Disease Patients to Enable AVF Creation (FACT)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* 18 and older~* Followed in the University of Chicago Medical Center's Nephrology Clinic~* Expected to initiate hemodialysis~* Estimated Glomerular Filtration Rate (eGFR) \<30 mL/min.1.73m~Exclusion criteria:~* Refusal/inability to give informed consent~* Inability to comply with trial requirements,~* Arm infections and/or skin disorders that require frequent medical attention.~* Patients with obvious scarring from IV drug use~* Previous phlebitis.~* Previous occluded arteriovenous grafts or fistulae~* Arterial aneurysms~* Arm deep vein thrombosis~* Any previous vascular surgery on the non-dominant arm.~* Limited cognitive ability~* Motor or sensory deficits in the upper arm~* Upon preliminary evaluation of the cephalic vein (measured 5 cm proximal to the styloid process of the radius, and at the antecubital fossa) there are no detectable superficial veins of at least 1.0 mm diameter, or superficial vein of more than 3.0 mm is present in this lower arm location.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Fist Assist device (all subjects) (Type: EXPERIMENTAL): All study subjects will have Stage 4 or 5 Chronic Kidney Disease (CKD) that requires them to start hemodialysis. In preparation for hemodialysis, they will have an arteriovenous fistula (AVF) procedure which provides access to the veins for dialysis.~This study is testing a device called the Fist Assist to dilate the vein in preparation for dialysis. The device is similar to a blood pressure cuff (worn around the arm and applies pressure). All study participants will wear the Fist Assist twice a day up to three months before their AVF procedure.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Antenatal Azithromycin to Prevent Preterm Birth in Pregnant Women With Vaginal Cerclage

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Gestational age (14-34 weeks).~2. Pregnant women who underwent vaginal cerclage (either history- based or ultrasound based vaginal cerclage)~History based cerclage:~* History of one or more second-trimester pregnancy losses related to painless cervical dilatation and in absence of labor or abruptio placentae; OR~* Prior cerclage due to painless cervical dilation in the second trimester~Ultrasound based cerclage:~Current singleton pregnancy, prior spontaneous preterm birth at less than 34 weeks of gestation, and short cervical length (less than 25 mm) before 24 weeks of gestation~Exclusion Criteria:~1. Multiple pregnancy.~2. Current or past history of medical diseases (Diabetes Milletus, Hypertension, Systemic Lupus Erythematosus, Cardiac diseases, etc ).~3. Adverse perinatal outcome due to abdominal trauma.~4. Structural fetal anomalies detected during anomaly scan.~5. Allergy to Azithromycin

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 35 Years
- Healthy Volunteers: f

Study Arms:
- Azithromycin group (Type: ACTIVE_COMPARATOR): women will receive 500mg Azithromycin (Zithrokan®, Hikma, Egypt) one tablet orally twice daily for three days in 3 courses at 14 weeks, 24 weeks and 32 weeks in addition to routine usual antenatal care.
- Control group (Type: NO_INTERVENTION): women will receive routine antenatal care without antibiotic prophylaxis after cerclage.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Treatment-Resistant Depression Registry

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patient diagnosed with a current major depressive episode according to DSM-IV-TR criteria.~* For D-21 patients only who have completed the D-21 dosing Study without any D-21 inclusion and exclusion protocol deviation.~* Patient has been in the current depressive episode for 2 years or longer, or has had at least 3 lifetime episodes including the current MDE.~* Patient has had an inadequate response to 4 or more adequate antidepressive treatments.~* The patient has a CGI severity of illness score of moderately ill (score of 4) or greater.~* The patient must be able to provide informed consent and complete all forms.~Exclusion Criteria:~* Patient has a history of schizophrenia, schizoaffective disorder, any other psychotic disorder, or a current major depressive episode that includes psychotic features; or is currently psychotic.~* Patient is currently enrolled in a double blind investigational study; patients who have completed the double-blind D-21 study will be allowed to enter the Registry for Long Term Follow-up~* Other than those patients who were enrolled in the D-21 study, patient has previously received VNS therapy.~* Patient has a history of rapid cycling bipolar disorder.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1. 500 VNS Patients (Type: None): VNS Patients - Treatment-resistant depression patients treated with VNS Therapy.
- 2. 300 Non-VNS Patients (Type: None): Non-VNS Patients - Treatment-resistant depression patients not receiving VNS Therapy.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Nepafenac Once Daily for Macular Edema - Study 1

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Planned cataract extraction by phacoemulsification with implantation of a posterior chamber intraocular lens;~* History of Type 1 or 2 diabetes and non-proliferative diabetic retinopathy (NPDR) (mild, moderate, or severe) in the study eye;~* Best corrected visual acuity (BCVA) of 73 letters or worse in the study eye with expectation of improvement after surgery;~* Understand and sign an informed consent document;~* Other protocol-defined inclusion criteria may apply.~Exclusion Criteria:~* Pre-existing macular edema in the study eye;~* History in the study eye of retinal detachment, wet age-related macular degeneration, chronic or recurrent inflammatory eye disease, or prior procedures;~* Planned cataract surgery in the fellow eye after randomization and prior to the Day 90 postoperative study visit or through study exit;~* Planned multiple procedures for the study eye during the cataract/intraocular lens implantation surgery;~* Use of exclusionary medications, including nonsteroidal anti-inflammatory drugs (NSAIDs) and steroids, as specified in protocol.~* Participation in any other clinical study within 30 days of the screening visit;~* Females of childbearing potential who are breast feeding, have a positive urine pregnancy test at screening, are not willing to undergo a urine pregnancy test upon entering or exiting the study, intend to become pregnant during the study, or do not agree to use adequate birth control methods for the duration of the study;~* Other protocol-defined exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Nepafenac (Type: EXPERIMENTAL): With prednisolone acetate standard of care, Nepafenac Ophthalmic Suspension, 0.3%, 1 drop instilled in the operative eye 1 day prior to surgery, continuing on the day of surgery, and for 90 days following surgery. An additional 1 drop will be administered 30 to 120 minutes prior to surgery.
- Vehicle (Type: PLACEBO_COMPARATOR): With prednisolone acetate standard of care, Nepafenac vehicle, 1 drop instilled in the operative eye 1 day prior to surgery, continuing on the day of surgery, and for 90 days following surgery. An additional 1 drop will be administered 30 to 120 minutes prior to surgery.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Hospice Problem Solving Intervention

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* enrolled as a family/informal caregiver of a hospice patient~* 18 years or older~* with access to a standard phone line or Internet and computer access at home~* without functional hearing loss or with a hearing aid that allows the participant to conduct telephone conversations as assessed by the research staff (by questioning and observing the caregiver)~* no or only mild cognitive impairment~* speak and read English, with at least a 6th-grade education~Exclusion Criteria:~* lack of phone or Internet access

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Attention Control (Type: NO_INTERVENTION): This group receives standard care with the attention of social support/ friendly interactions and serves as an attention control group.
- Intervention Group 1 (Face to Face) (Type: EXPERIMENTAL): This group receives Problem Solving Therapy in face to face visits.
- Intervention Group 2 (Video) (Type: EXPERIMENTAL): This group receives Problem Solving Therapy via video.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Optimization of the Ambulatory Monitoring for Patients With Heart Failure by Tele-cardiology

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Aged 18 years or older~* Men or women patient with heart failure having been hospitalized for cardiac decompensation during the last 12 months.~* Patient with access to a wireline telephone service or GPRS network.~* The patient is willing and able to sign an informed written consent~* Patient is insured under the social security system~Exclusion Criteria:~* No available echocardiographic evaluation.~* BNP lower than 100pg/ml or NT-proBNP lower than 300pg/ml~* A prognosis of a life span of less than 12 months (apart from heart failure)~* Dialysis patients~* Heart transplant or cardiac assist devices~* Patients involved in inotropic treatment~* Patient doesn't have the necessary autonomy to use the equipment~* Patient enrolled in another clinical trial~* A pregnant or nursing woman, or patient of reproductive age who doesn't use contraceptives~* Patients under tutorship, curatorship or judicial protection~Inclusion Criteria in the extension period:~Participation in the open extension period is only offered to patients who participated in the comparative period of the study, did not withdraw prematurely from the latter and gave their free informed written consent to participate to the extension period.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Standard care (Type: NO_INTERVENTION): Standard follow-up, with conventional monitoring involving consultations and monitoring by their general practitioners or referring cardiologists
- Tele-cardiology group (Type: EXPERIMENTAL): Telecardiology Program

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete